IGC Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IGC Pharma, Inc. (IGC) on December 15, 2025, reporting events occurring on December 12, 2025. The Company is incorporated in Maryland and its common stock trades on the NYSE American under the symbol "IGC".
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on a corporate governance action regarding the Company's capital structure.
Material Changes
Effective December 12, 2025, the Company amended its Amended and Restated Articles of Incorporation to increase its authorized common stock. This change was approved by stockholders at the Annual Stockholders Meeting on October 10, 2025, and filed with the Maryland State Department of Assessments and Taxation (SDAT).
- Authorized Common Stock: Increased from 150,000,000 shares to 600,000,000 shares.
- Authorized Preferred Stock: Remained unchanged at 1,000,000 shares.
- Total Authorized Shares: Increased from 150,000,000 to 601,000,000 shares.
- Aggregate Par Value: Increased from $15,100.00 to $60,100.00.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the amendment to the Articles of Incorporation.
Key Facts for Investor Verification
- Verify the effective date of the stock authorization increase (December 12, 2025).
- Confirm the new total authorized share count of 601,000,000 (600M Common, 1M Preferred).
- Note that this filing does not report any change in the number of shares currently outstanding, only the authorized limit.
- Review Exhibit 3.1 for the full text of the Articles of Amendment filed with Maryland SDAT.